TechCrunch : Tesla’s energy storage business gets sucked into the company’s down

Tesla’s energy storage business gets sucked into the company’s downward spiral

Even Tesla’s energy storage business, which has been a small, yet notable bright spot, can’t escape the cloud that’s hanging over the company.

For the second consecutive quarter, deployments of its Powerwall and Megapack stationary storage products have declined, according to stats released by Tesla. In the second quarter of this year, the company installed 9.6 gigawatt-hours of storage, down 0.8 gigawatt-hours from the first quarter.

Tesla’s energy storage division peaked in the fourth quarter of 2024, a three-month period that saw 11 gigawatt-hours deployed. In all, Tesla deployed 31.4 GWh of energy storage products in 2024.

Until this year, the sector has been a bright spot for Tesla, posting consistent year-over-year growth. Revenue from energy storage and solar installations grew from $2 billion in 2020 to $10.1 billion last year. Tesla’s poor start to the year suggests that streak is about to come to an end.

By contrast, the broader market for energy storage has been growing recently. Analysts at Wood Mackenzie said new installations hit a record high in Q1, the most recent period for which data is available, growing by 57% year-over-year.

Such growth is unlikely to continue, though, as tariffs on Chinese-made goods coincide with the ill-effects of a Trump-backed reconciliation bill currently being hashed out in Congress. There, Republicans have been working to eliminate key parts of the Inflation Reduction Act.

While battery storage installations might continue to receive tax credits under the bill, new restrictions over parts or materials sourced from foreign entities of concern (FEOC) could make any remaining tax credits nearly impossible to claim. The vast majority of minerals used in batteries are refined or processed in China.

WSJ : Women Are Spending Big Money for Little Breast Implants

Women Are Spending Big Money for Little Breast Implants
In the age of Ozempic, patients are downsizing their implants and seeking surgeries that offer subtle enhancement. One surgeon called the trend ‘Park Avenue quiet luxury.’

Vale Genta spent years googling “tiny boob job” before she found a surgeon who could give her the “perky” B cup of her dreams. “I just wanted a little oomph,” said the 27-year-old content creator, who lives in Miami.

So two summers ago, Genta spent $9,000 to get 200-cubic-centimeter implants that took her one cup-size up from her natural A. When she shared details about her implants on TikTok in early June, she was flooded with comments from fans also looking for a tiny enhancement.

“We all want little perky boobs,” Genta said.

Plastic surgery has not always been known for subtlety. But when it comes to breasts, more patients are asking for enhancements that are barely noticeable. Where DDs used to be the goal in operating rooms, now women are requesting Bs and small Cs suited to shifting aesthetics. In the Ozempic era, the aspirational feminine physique has moved away from curvy and voluminous and toward bodies that are fit.

“They call them Ballerina Boobs,” said Dr. Payman Danielpour, a plastic surgeon in Beverly Hills. “We’re using subtle, cute, nice implants.” He charges clients around $20,000 for the procedure.

Breast augmentation was the second-most popular cosmetic surgery in the U.S. last year, at 306,196 procedures, according to the American Society of Plastic Surgeons, just behind liposuction.

Between 2013 and 2018, medium-size implants of 300 to 500 cubic centimeters made up 69% of breast-implant sales at Mentor, a leading implant supplier. Surgeons and implant makers now say demand for smaller implants is rising.

The sales of implants 250 cubic centimeters and under grew double digits from 2023 to 2024 at Allergan, the company said.

In Utah, plastic surgeon Dr. Jerry Chidester said implants in the range of 180 to 250 cubic centimeters at his practice had increased 250% from 2022 to 2024.

“On average, instead of women going to a DD cup, they are going to a full C,” said Chidester.

In New York City, Dr. Ira Savetsky said that three years ago he had mostly worked with implants in the 330 to 350 cubic centimeters range, but now mainly did implants sized 190 to 250 cubic centimeters.

Cubic-centimeter measurements don’t quite correlate to cup size because women’s bodies can vary, but Savetsky estimates the desired aesthetic has gone from a small D to big B. Women are seeking breasts that are “understated,” Savetsky said, noting that on the Upper East Side, small implants are now considered “the Park Avenue quiet luxury.”

Surgeons say advancements in the field of breast augmentation have helped contribute to the rise of smaller and more subtle augmentations. Some doctors are trading implants for fat transfers, taking from the stomach or thighs and injecting it into the breast. Chidester said he also worked with harvested fat cells from cadavers. Doctors are also working with “internal bras” for breast lifts, where a scaffold helps with support and eventually dissolves once the body replaces it with collagen.

The entrant of implants from Motiva, a medical-technology company that obtained U.S. Food and Drug Administration approval last September, has also been a “game-changer,” Danielpour said. About one-third of Motiva implants sold in the U.S. from late 2024 through May 2025 were under 300 cubic centimeters, a spokeswoman for parent company, Establishment Labs, said. Newer-generation implants like Motiva’s are well suited to be placed above the muscle, said Chidester, which can yield more natural results because of their “softer, more adaptive design.”

“Times change, styles change, like eyebrows,” said Jennifer Fisher, a jewelry designer and entrepreneur in Los Angeles, who recently downsized her implants. “A lot of my friends considering this surgery now just want a little bit of a lift.”

A fitness-focused lifestyle is changing the coveted female aesthetic.

“People are aspiring to be lean, long and flexible,” said Danielpour, in Beverly Hills. “No one wants to be busting out of their Alo” (as in the yoga brand).

Women with larger implants who have lost weight with GLP-1s “now want breasts proportionate to their bodies,” said Savetsky. Those with natural breasts can also sometimes experience something doctors call “Ozempic breasts.”

“The breasts are becoming super deflated,” said Danielpour. “Everything is sagging, so one way or another, they have to do something. But they say, ‘go as small as you can go.’ They don’t want to look busty.”

Plastic surgery is no longer considered taboo, and many people now speak openly about their surgeries online. On TikTok, the cherry emoji has become the official symbol for smaller implants.

That open dialogue helped convince Jackie Boyle, a 30-year-old dialysis nurse in Boston, to take the plunge and get breast implants last April.

Boyle said she’d wanted breast enhancement surgery since she was 15, and followed other women posting about their #naturalboobjobs on TikTok before she got hers. She opted for 300-cubic-centimeter implants to bring her to a B cup.

“I wanted something where I’d look good in sports bras but not in your face,” she said. Boyle said her new breasts gave her confidence. “You can dress them up and or dress or down. You can wear them without a bra and have nice, little cleavage or wear them with a bra and have a girl’s night out.”

Breast augmentation surgery comes with potential risks. Women with silicone implants have reported complications including pain, distorted breasts and a rare form of cancer. This may be why some women are opting for fat transfers or breast lifts.

Kelsey Rose, a 33-year-old fitness instructor in Miami, got small, 180-cubic-centimeter implants in December. She initially did a fat transfer to her breasts, but the procedure didn’t have lasting results. Her goal, she said, was to have breast implants that were undetectable: “You look at me and you’re like, ‘Did she?’”

Rose believes that fitness as a lifestyle has directly impacted the popularity of smaller breast augmentations. “You don’t really see the classic Pilates girl with big, massive boobs,” she said.

Dr. Anna Steve’s TikTok bio describes her as “specializing in small volume, elegant implants 🍒.” Breast augmentations start at $18,500 at her New York office, where she says 30% of her patients come from out of state.

The plastic surgeon is often swapping D and double-D implants for “perky Bs and small Cs.” But she also works with menopausal women “who gain breast volume and overwhelmingly feel matronly.” Steve has also identified a huge market for small implants in mothers, she said, “who’ve always identified as small-breasted but then lost volume” due to breast-feeding or aging.

Amy Levy, a 48-year-old mom of two in Los Angeles, got small implants in March to take her to a small C cup. She said she’d never considered surgery until perimenopause. “They got absolutely deflated,” she said. Now, she said, they’re full again, but not imposingly so. “They still look and feel like me.”

Racquel Bettencourt, an influencer and swimsuit-brand owner in Miami, decided to remove her implants entirely in November, after struggling for years with pain and discomfort.

“At 24, I had a tiny body and wanted to feel more like a woman,” said Bettencourt, 38. “But now, I’m very happy to be my natural self. I don’t give a s—what they look like.”

>>> Olo Inc. has entered into a definitive agreement to be acquired by Thoma Bra

Olo Inc. has entered into a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valuing Olo at approximately $2.0 billion in equity value (8.91)
  • The transaction is expected to help accelerate Olo's growth and strengthen its platform and offerings for the over 750 restaurant brands it serves globally. Upon completion of the transaction, Olo will become a privately held company.
  • Under the terms of the agreement, Olo shareholders will receive $10.25 per share in cash. The per-share purchase price represents a premium of 65% over Olo's unaffected share price of $6.20 as of April 30, 2025, the last trading day prior to media reports regarding a potential transaction.
  • The transaction, which was unanimouslyapproved by the Olo Board of Directors, is expected to close by the end of calendar year 2025, subject to customary closing conditions, including approval by Olo shareholders and the receipt of required regulatory approvals. The transaction is not subject to a financing condition.
  • Upon completion of the transaction, Olo common stock will no longer be listed on any public stock exchange. The Company will continue to operate under the Olo name and brand.

>>> US Research Calls I

Research Calls I
  • Upgrades
    • FedEx (FDX) upgraded to Outperform from Underperform at BNP Paribas Exane, tgt $270
    • Huntington Bancshares (HBAN) upgraded to Outperform from Peer Perform at Wolfe Research, tgt $21
    • Meta Platforms (META) upgraded to Hold from Underperform at Needham
    • UPS (UPS) upgraded to Neutral from Underperform at BNP Paribas Exane; tgt $100
    • Valley National (VLY) upgraded to Overweight from Equal Weight at Morgan Stanley, tgt $11
  • Downgrades
    • NV5 Global (NVEE) downgraded to Hold from Buy at Maxim Group
    • PNC Financial (PNC) downgraded to Peer Perform from Outperform at Wolfe Research
    • Rio Tinto (RIO) downgraded to Hold from Buy at Berenberg
    • Theratechnologies (THTX) downgraded to Hold from Buy at JonesResearch
    • Two Harbors (TWO) downgraded to Market Perform from Outperform at Citizens JMP
  • Others
    • Absci (ABSI) assumed with an Overweight at Morgan Stanley, tgt $7
    • Argenx (ARGX) assumed with an Overweight at Morgan Stanley, tgt $700
    • Ascendis Pharma (ASND) assumed with an Overweight at Morgan Stanley, tgt $250
    • Axsome Therapeutics (AXSM) assumed with an Overweight at Morgan Stanley, tgt $190
    • BioMarin Pharmaceutical (BMRN) resumed with an Overweight at Morgan Stanley; tgt $97
    • Certara (CERT) resumed with an Equal-Weight at Morgan Stanley; tgt $16
    • Disc Medicine (IRON) resumed with an Overweight at Morgan Stanley; tgt $85
    • Kymera Therapeutics (KYMR) assumed with an Overweight at Morgan Stanley, tgt $70
    • Prairie Operating (PROP) initiated with a Sector Weight at KeyBanc
    • Primoris Services (PRIM) initiated with a Buy at Janney
    • Ralliant (RAL) initiated with an Underperform at BofA Securities, tgt $48
    • Recursion Pharmaceuticals (RXRX) assumed with an Equal Weight at Morgan Stanley, tgt $5
    • Sana Biotechnology (SANA) assumed with an Overweight at Morgan Stanley, tgt $12
    • Schrodinger (SDGR) assumed with an Equal Weight at Morgan Stanley, tgt $28
    • Telix Pharmaceuticals (TLX) initiated with a Buy at H.C. Wainwright, tgt $23

FT : Chris Hohn’s hedge fund TCI beats stock markets with 21% gain

Chris Hohn’s hedge fund TCI beats stock markets with 21% gain
Bets on GE Aerospace, Microsoft and Visa help activist fund to first-half profits

Sir Christopher Hohn’s activist hedge fund TCI has risen 21 per cent so far this year, according to two people who have seen the numbers, as bets on jet engine manufacturer GE Aerospace, Visa and Microsoft came good.

The gains for The Children’s Investment Fund, which manages just over $70bn in assets, are more than triple the returns of the US S&P 500 index, and reinforce Hohn’s status as one of the world’s most successful equity hedge fund managers.

TCI has held a multibillion-dollar stake in GE Aerospace, which has soared 47 per cent this year, according to US regulatory disclosures. The company makes jet engines for commercial and military applications and was spun out of General Electric following the conglomerate’s break-up last year. The fund held a $7.7bn stake as at the end of last year, and a $9.5bn position as of the end of March, according to the disclosures.

The fund also benefited from its multibillion-dollar stake in Microsoft, a position it has held on and off for some time and which has climbed 17 per cent this year. In addition, it has profited from a position in US payments company Visa, which is up 12 per cent.

However, stocks it has been holding, such as Canadian National Railway and Alphabet, the parent company of Google, are both slightly down so far this year.

WSJ : JPMorgan Is Revamping Its Bank for the Superrich to Cater to Global Client

JPMorgan Is Revamping Its Bank for the Superrich to Cater to Global Clientele
David Frame named global head of the private bank, helping deep-pocketed clients invest more abroad

  • JPMorgan Chase is reorganizing its private bank to better serve wealthy clients seeking to safeguard their wealth globally.
  • Growing global conflicts and trade-war risks have made top earners wary of keeping their money in one country.
  • David Frame will become global head of the private bank, a new role, as clients are treated as a group instead of by nation.

JPMorgan Chase JPM 0.55%increase; green up pointing triangle is reorganizing its private bank to better serve the world’s richest people, who want to safeguard their wealth by spreading it around the globe.

With a minimum required balance of $10 million, JPMorgan’s white-glove bank for the superrich is one of the preferred places for the world’s elite to store their wealth. These customers are demanding that JPMorgan invest more of their money abroad, not just in the country where they spend the bulk of their time.

Growing conflicts in the Middle East and the risk of a global trade war have made top clients more wary of keeping their money in one country or region of the world. Investors outside the U.S. also want to diversify their portfolios, attracted by the boom in private markets.

“Our clients have always been multi-jurisdictional but now their assets are too, and that’s becoming ever more so with how the world is changing,” said Mary Erdoes, head of JPMorgan’s asset and wealth management unit, in an interview.

On Thursday, Erdoes announced internally that David Frame would become global head of the private bank, a new role inside the organization. Frame previously served as the U.S. head, as JPMorgan’s bank for the rich had been set up more to focus on clients in individual countries.

David Frame has been named global head of JPMorgan’s private bank. Photo: JPMorgan Chase
JPMorgan executives say that is an increasingly outdated way of serving the world’s wealthiest.

“The wealthier you get, the more you feel you’re a citizen of the world,” Frame said in an interview. “If that doesn’t happen with the first generation of a family, it starts to happen with the second and the third.”

Erdoes said that JPMorgan’s private bank has already been busy helping its clients invest their money worldwide. When the German automaker Porsche started to work with JPMorgan’s investment bank for an initial public offering in 2022, it tapped the private bank to reach out to nearly 60 high-net-worth investors across the world to help build a book of orders for the stock.

Ultimately, 10 of the private bank’s high-net-worth clients participated in the deal, which was Europe’s largest IPO in over a decade. Each invested more than $100 million. Porsche shares are down nearly 50% since then.

Clients from around the world are also looking to invest in sports teams, which are commanding sky-high valuations as wealthy families pour billions into these franchises. When Boston Celtics owner Wyc Grousbeck started working with JPMorgan to find buyers for the franchise, the private bank contacted some 186 international clients to gauge their interest in the deal.

Frame said the deals show it makes more sense to treat these uber-rich clients as a group instead of siloing them by nationality.

“There are borders for sports teams, but it doesn’t feel that way when it comes to the wealthy who are investing in them,” Frame said.